22nd week of 2017 patent applcation highlights part 7 |
Patent application number | Title | Published |
20170151276 | METHOD AND PHARMACEUTICAL TO TREAT SPINAL DISCS - Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a solution is injected into the disc. The solution includes chondroitin sulphate, glucosamine HCl, and dextrose. The solution may optionally include dimethyl sulfoxide and/or an anesthetic such as bupivicaine. | 2017-06-01 |
20170151277 | ENHANCED IMMUNE RESPONSE IN CATTLE UPON TREATMENT WITH NITRIC OXIDE - The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease. | 2017-06-01 |
20170151278 | THERAPEUTIC GAS RELEASING SYSTEM - The present invention relates to therapeutic gas releasing systems. The system comprises compounds A and B, wherein A is a therapeutic gas releasing molecule, A and B are not in contact with each other in the therapeutic system during storage, and B enhances therapeutic gas release from A when the therapeutic system is administered to a patient. | 2017-06-01 |
20170151279 | EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate. | 2017-06-01 |
20170151280 | TREATMENT METHODS AND BIOLOGICALLY ACTIVE PREPARATIONS USING BLOOD OF A DONOR SUBJECTED TO REMOTE CONDITIONING - Treatment methods are described using blood collected from a donor after subjecting thereof to remote conditioning such as remote ischemic conditioning via several episodes of short-term limb occlusion. Blood containing remote conditioning substances or a biologically active preparation containing such substances may be stored and used at a future time to afford a health benefit to the treatment subject. Extraction of remote conditioning substances may be done extracorporeally using dialysis or other blood processing methods following by returning of blood to the donor. Extraction of remote conditioning substances may be done during the time periods of their maximum presence in donor blood. | 2017-06-01 |
20170151281 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER - The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC. | 2017-06-01 |
20170151282 | COMPOSITIONS AND METHODS FOR SELECTIVE PHAGOCYTOSIS OF HUMAN CANCER CELLS - The present invention relates to compositions and methods that provide novel therapies in cancer. The invention includes a phagocytic cell modified with a repressor of signal regulatory protein-alpha (SIRPα) and bound to a targeting antibody to enhance phagocytic activity of the phagocytic cell toward tumor tissue. Methods of enhancing phagocytic activity and treating a tumor are also included. | 2017-06-01 |
20170151283 | COMPOSITIONS AND METHODS FOR TREATING ANTIBODY RESISTANCE - The invention provides compositions and methods for overcoming poor response to antibody therapy, for example, antibody resistance. The invention also relates to at least one immune receptor (IR) specific to the Fc receptor, vectors comprising the same, and recombinant T cells comprising the Fc immune receptor. The invention also includes methods of administering a modified T cell expressing an immune receptor that comprises a Fc binding domain. | 2017-06-01 |
20170151284 | MESENCHYMAL STROMAL CELLS FOR TREATING SEPSIS - The invention relates to the use of mesenchymal stromal cells (MSCs) for treating sepsis in a subject. The invention provides compositions, uses and methods for the treatment of sepsis. | 2017-06-01 |
20170151285 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS - The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed. | 2017-06-01 |
20170151286 | COMPOSITIONS AND METHODS FOR PREPARING AN INJECTABLE MEDIUM FOR ADMINISTRATION INTO THE CENTRAL NERVOUS SYSTEM - Injectable mediums and methods for preparing and administering an injectable medium comprising therapeutic cells, and optionally one or more therapeutic or diagnostic substance, suitable for injection into an anatomical space of a human or animal subject, comprising hyaluronic acid in concentrations of 0.5 weight percent to 1.0 weight percent having a molecular weight of about ≧700 kDa to about 1,900 kDa and a storage modulus within the range of 5-25 Pa, which injectable mediums and methods prevent cell settling during transportation and storage of such injectable mediums comprising therapeutic cells, and optionally therapeutic or diagnostic substances; promote cell survival; facilitate administration of homogeneous injectable mediums comprising therapeutic cells, in particular NSCs; and enable rapid clearance by the body following injection, so as not to interfere with cellular integration with surrounding tissue. | 2017-06-01 |
20170151287 | METHODS AND COMPOSITIONS OF CHONDRISOMES - Therapeutic chondrisome compositions and related methods are described. | 2017-06-01 |
20170151288 | CELL THERAPY PREPARATION INDUCING THE RELEASE OF CELLULAR SUBSTANCES FOR TISSUE REGENERATION - Provided is a tissue regeneration material release-inducing cell therapeutic composition including a medium for cryopreservation of an animal cell which contains a protein, a sugar, a buffer, and a basal medium and does not contain DMSO, glycerol, and serum. The cell therapeutic composition of the present invention is characterized in that both an animal cell and the medium for cryopreservation of an animal cell have tissue regeneration efficacy, as a tissue regeneration accelerating material within cells is released into the medium for cryopreservation through freezing and thawing processes of the cells. In addition, the cell therapeutic composition of the present invention may be directly cryopreserved in a vial, ampoule or pre-filled syringe, thereby being highly convenient for use, and does not use a cryopreservative agent and serum and thus may be directly applied to a lesion without a separate washing process. | 2017-06-01 |
20170151289 | FORMULATIONS AND METHODS FOR TREATMENT OF WOUNDS AND INFLAMMATORY SKIN CONDITIONS - The disclosure of the present application includes topically administrable compositions and methods for treating wounds and inflammatory conditions of the skin in mammals. In an exemplary embodiment, the composition includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more of these; a therapeutic amount of creatine; a therapeutic amount of creatinine; and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination of these. The combination of non-sedating antihistamine, creatine, and creatinine with emu oil has been found to produce a synergistic effect that is more effective in the treatment of skin wounds than the compounds used separately. | 2017-06-01 |
20170151290 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS BY CHARACTERIZING AND RESTORING MAMMALIAN BACTERIAL MICROBIOTA - The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota. | 2017-06-01 |
20170151291 | SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF - Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human. | 2017-06-01 |
20170151292 | CRYOPROTECTANTS FOR FREEZE DRYING OF LACTIC ACID BACTERIA - The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications. More in particular, the invention relates to the increased viability and long-term storage of recombinant bacteria capable of expressing heterologous proteins or peptides and administered to humans or animals for therapeutic or vaccination purposes. | 2017-06-01 |
20170151293 | Method and System for Protecting Honey Bees, Bats and Butterflies from Neonicotinoid Pesticides - A method and system for the treatment of honey bees ( | 2017-06-01 |
20170151294 | METHOD FOR PROTECTING KIDNEY FUNCTION - The present invention relates to a method for protecting a kidney, which comprises administering an extracellular polysaccharide produced by | 2017-06-01 |
20170151295 | USE OF CHI-JU-DI-HUANG-WAN IN TREATING RETINAL ISCHEMIA OR A DISEASE, CONDITION, OR DISORDER ASSOCIATED WITH RETINAL ISCHEMIA - The present invention relates to a method for treating retinal ischemia, or a disease, condition, or disorder associated with retinal ischemia, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a composition comprising Chi-Ju-Di-Huang-Wan, wherein the Chi-Ju-Di-Huang-Wan consists of Rehmanniae Radix Preparata, Corni Fructus, Rhizoma Diocoreae, Poria, Cortex Moutan Redicis, Alismatis Rhizome, Fructus Lycii, and Chrysanthemi Flos. | 2017-06-01 |
20170151296 | COMPOSITION AND USE THEREOF - The present invention discloses a composition and use. The composition comprises hemp seed oil and algal oil with a mass ratio of (20˜60):(30˜70). After a large number of screening studies on concerted application, the present inventors found that the composition has synergistic effects, specifically, it has significant inhibitory effects on weight gain of animal model rats for hyperlipidemia, can significantly increase the hypolipidemic efficacy, and has an anti-oxidation effect. In addition, the composition of the present invention has efficacies of improving learning and memory abilities, improving constipation, and protecting the liver. Medicaments and functional food made from the composition of the present invention are simple in production process, stable in product quality, clear in functional factor, prominent in health care efficacy, low in administration dosage, safe in use, without toxic and side effects, and are suitable for consumption of the general population. | 2017-06-01 |
20170151297 | METHOD FOR IMPROVING MITOCHONDRIA AND METHOD FOR PROMOTING CELL DIVISION OF STEM CELL - The present disclosure is related to a method for improving mitochondria in a cell, comprising step of treating the cell with an extraction of | 2017-06-01 |
20170151298 | Medicinal Composition of Extract of Seed of Emblica Officinalis and Method of Preparing the Same - An extract of seeds of | 2017-06-01 |
20170151299 | EXTRACTS OF SANTOLINA CHAMAECYPARISSUS - The invention relates to an extract of | 2017-06-01 |
20170151300 | NUTRITIONAL SUPPLEMENT FOR THE ENHANCEMENT OF MUSCLE IRISIN AND ENHANCEMENT OF BROWN FAT, METABOLIC RATE, AND WEIGHT LOSS, AND METHODS OF USE THEREOF - The present invention includes a method of activating irisin by administering to an individual in need of such treatment a composition comprising irisin-activating ingredients, thus increasing the conversion of white fat to BAT, and consequently, increasing metabolic rate and promoting weight loss. In an embodiment, the composition includes a | 2017-06-01 |
20170151301 | Biologically active food additive for normalizing the function of the thyroid gland - A biologically active food additive for normalizing the function of the thyroid gland comprises roots or rhizome or the above-ground part of white cinquefoil, or a mixture thereof, purple echinacca and laminaria, with the following ratio of components in mass %: 10-75 of white cinquefoil, 10-50 of purple echinacea and 10-80 of laminaria. The technical result of the invention is the showing of increased efficacy in treating thyroid gland disorders and enhancing the body's immune status, with no side of ects. | 2017-06-01 |
20170151302 | Compositions and Methods for Alleviating Hyposalivation and for Providing Oral Comfort - Various compositions and methods are provided to alleviate one or more symptoms associated with hyposalivation and/or xerostomia. Preferred compositions and methods employ one or more plant pulp products and/or a proanthocyanidin at a concentration effective to reduce or eliminate the symptoms. Especially preferred product components are isolated from a fruit and/or seed (e.g., grape, cranberry, blue berry, black berry, etc.), and where a second component is preferably a freeze-dried pulp from a citrus fruit (e.g., lemon, orange, lime, grapefruit, tangerine, mandarin orange, ugli fruit, etc.) not containing peel or juice therein. | 2017-06-01 |
20170151303 | Compositions and Methods for Alleviating Hyposalivation and for Providing Oral Comfort - Various compositions and methods are provided to alleviate one or more symptoms associated with hyposalivation and/or xerostomia. Preferred compositions and methods employ one or more plant pulp products and/or a proanthocyanidin at a concentration effective to reduce or eliminate the symptoms. Especially preferred product components are isolated from a fruit and/or seed (e.g., grape, cranberry, blue berry, black berry, etc.), and where a second component is is preferably a freeze-dried pulp from a citrus fruit (e.g., lemon, orange, lime, grapefruit, tangerine, mandarin orange, ugli fruit, etc.) not containing peel or juice therein. | 2017-06-01 |
20170151304 | ANTI-PROLIFERATIVE EFFECTS OF PALM VEGETATION LIQUOR AND EXTRACTS THEREOF IN PREVENTING PANCREATIC CANCER - Present invention relates to a composition to inhibit cancer cell proliferation, wherein said composition comprises oil palm extracts. The composition is useful for prevention of pancreatic cancer by inhibiting clonogenicity, inducing apoptosis, regulating gene expression, inducing anti-invasive effect, and induces cell cycle arrest in S phase. Present invention also discloses a composition that inhibits NF-κB activity and reduces cell invasion, cell migration and metastasis. Present invention further discloses the use of therapeutically effective amount of a composition in inhibiting the growth of pancreatic cancer. | 2017-06-01 |
20170151305 | Combination Therapy with Peptide Epoxyketones - The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent. | 2017-06-01 |
20170151306 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS - The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds. | 2017-06-01 |
20170151307 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO - The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. | 2017-06-01 |
20170151308 | METHOD FOR IDENTIFYING, EXPANDING, AND REMOVING ADULT STEM CELLS AND CANCER STEM CELLS - The invention relates to the fields of biochemistry, pharmacy and oncology. The invention particularly relates to the use of novel stem cell markers for the isolation of stem cells. The invention further relates to the obtained stem cells and their use in for example research or treatment, for example, for the preparation of a medicament for the treatment of damaged or diseased tissue. | 2017-06-01 |
20170151309 | PEPTIDE AND USES THEREFOR - Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N′-SVTEQGAELSNEER-C′ (SEQ ID NO: 1) or an analogue thereof that inhibits T cell migration. Also provided is the peptide or its analogue for use in the methods of treatment and/or prophylaxis of said condition. Also provided is a method for the treatment of Sjogren's syndrome by administration of a peptide comprising N′-SVTEQGAELSNEER-C′ to a patient in need thereof. | 2017-06-01 |
20170151310 | COMPLEXES OF IL-15 AND IL-15RALPHA AND USES THEREOF - The present invention relates to agents that modulate interleυkin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-β-1-♦4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function. | 2017-06-01 |
20170151311 | Method of treating dyspnea associated with acute heart failure - The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin. | 2017-06-01 |
20170151312 | METHODS AND PRODUCTS RELATING TO GSK3 REGULATION - The invention relates to methods and compositions for regulation of GSK3β activity. The invention provides phosphorylated GSK3β polypeptides and antibodies that recognize such polypeptides The invention further includes methods for treating disorders that are associated with elevated or reduced GSK3β activity. | 2017-06-01 |
20170151313 | LIPID HYDROLYSIS THERAPY FOR ATHEROSCLEROSIS AND RELATED DISEASES - The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides. | 2017-06-01 |
20170151314 | COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME - A debridement enzyme for necrotic tissue is described that is not dependent upon proteolytic enzymatic activity but instead utilizes the amylase family of enzymes. The amylases (α-, β-, γ-amylase) are noted for the cleavage of the α-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments. It has now been found that α-amylase is effective in the debridement of devitalized tissue. | 2017-06-01 |
20170151315 | Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients - A method of reducing or treating parainfluenza or influenza virus infection in an immunocompromised patient by administering to the respiratory tract of the patient a composition comprising a therapeutically effective amount of protein having sialidase activity. | 2017-06-01 |
20170151316 | METHODS OF INCREASING MUSCLE MASS USING NON-TOXIC TETANUS TOXIN C FRAGMENT (TTC) - The present disclosure relates to the use of the non-toxic proteolytic C fragment of tetanus toxin and plasmids encoding such protein fragment to increase muscle mass and/or muscle strength in a subject in need thereof. As such, methods of ameliorating the severity of a pathological condition characterized, at least in part, by a decreased amount, development, or metabolic activity of muscle are provided. The disclosed compositions and method are also useful for the treatment of condition in which increase in muscle mass and muscle strength are desirable, including cosmetic uses. | 2017-06-01 |
20170151317 | PEPTIDE ANALOGS CAPABLE OF ENHANCING STIMULATION OF A GLIOMA-SPECIFIC CTL RESPONSE - The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. | 2017-06-01 |
20170151318 | ANTI-MYCOPLASMA SPP. SUBUNIT VACCINE - Provided in the present invention are anti- | 2017-06-01 |
20170151319 | IMMUNOGENIC COMPOSITION FOR MODULATING THE IMMUNE SYSTEM AND METHODS TO TREAT BACTERIAL INFECTIONS IN A SUBJECT - The present invention refers to pharmaceutical products comprising immunogenic compositions for modulating the immune system, which comprise a therapeutically effective amount of a Immunological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS), in association with an antibiotic and one or more physiologically acceptable carriers, excipients, diluents or solvents. IN other embodiments, the present invention refers to methods to treat severe bacterial infections, sepsis and modulating the immune system. | 2017-06-01 |
20170151320 | Vaccines For Human Papilloma Virus And Methods For Using The Same - Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed. | 2017-06-01 |
20170151321 | CHIMERIC PESTIVIRUSES - The present invention relates to chimeric pestiviruses having utility as immunogenic compositions and vaccines. Also described herein are methods and kits for treating or preventing the spread of bovine viral diarrhea virus infection, as well as methods and kits for differentiating between vaccinated and wild-type infected animals. | 2017-06-01 |
20170151322 | CELL LINES FOR VIRUS PRODUCTION AND METHODS OF USE - Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picomavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection. | 2017-06-01 |
20170151323 | RECOMBINANT SWINE INFLUENZA VIRUS AND USES THEREOF - Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the recombinant influenza viruses, immunogenic compositions comprising the recombinant influenza viruses, methods of stimulating an immune response against influenza virus, and methods of treating and preventing influenza virus infection. | 2017-06-01 |
20170151324 | Genetically Engineered Swine Influenza Virus And Uses Thereof - The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 2017-06-01 |
20170151325 | COMPOSITIONS OF FOOD ALLERGENS - The invention relates to novel compositions and methods for diagnosing or treating food allergies. The invention particularly discloses new approaches for delivering food allergens to allergic patients by oral administration of formulations which dissolve and release proteins in the stomach. The invention allows the treatment of food allergies by delivering food allergens to the gut immune system with controlled exposure of the esophagus or oral cavity. The invention also allows to perform food challenges to assess the threshold of clinical reactivity without exposing the esophagus and oral cavity. The invention may be used in any subject, particularly human subjects, and is applicable to any food allergen. | 2017-06-01 |
20170151326 | IMMUNITY INDUCER - Disclosed is an immunity inducer. The immunity inducer comprises virus like particles; the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen; the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat; and the virus like particles induce an immune effect of a living body on the antigen. | 2017-06-01 |
20170151327 | INDUCTION OF IMMUNOTOLERANCE - The present invention provides for a novel method for inhibiting an undesirable immune response, especially in transplant recipients such as those having received an allogeneic stem cell transplant. Also disclosed are related compositions and kits for inducing immunotolerance. | 2017-06-01 |
20170151328 | HIGH CONCENTRATION FORMULATIONS OF ANTI-C5 ANTIBODIES - The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component C5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions. Also featured are therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment. | 2017-06-01 |
20170151329 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2017-06-01 |
20170151330 | ULTRASOUND DELIVERY OF NANOPARTICLES - Enhanced delivery of compositions for treatment of skin tissue with photoactive plasmonic nanoparticles and light, with embodiments relating to delivery devices using, for example, ultrasound. Treatments are useful for cosmetic, diagnostic and therapeutic applications. | 2017-06-01 |
20170151331 | NANOSTARS AND NANOCONSTRUCTS FOR DETECTION, IMAGING, AND THERAPY - A polymer-free synthesis method is provided for preparation of monodisperse nanostars. The nanostars can be used for treating and imaging cells in in vivo or ex vivo. The modes of treatment include use of a nanostar modified with a photo-activatable drug, which drug is activated by the photo-response of the nanostar to electromagnetic stimulation; use of a nanostar modified with a thermally-activatable drug, which drug is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which can directly or indirectly cause the death of an undesirable cell. | 2017-06-01 |
20170151332 | BIOPHOTONIC MATERIALS AND USES THEREOF - The present disclosure provides biophotonic materials and methods useful in phototherapy. In particular, the biophotonic materials of the present disclosure include a cohesive matrix, and at least one chromophore, wherein the at least one chromophore can absorb and emit light from within the biophotonic material. The biophotonic materials and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various skin disorders. | 2017-06-01 |
20170151333 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 2017-06-01 |
20170151334 | INJECTABLE AND IMPLANTABLE CARRIER SYSTEMS BASED ON MODIFIED POLY(DICARBOXYLIC ACID MULTI-OIL ESTERS) FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENT - Modified poly(dicarboxylic acid multiol esters) are suitable as carriers for bioactive substances, especially as injectable implants, without further additives. The polymers can be directly injected without using an organic solvent. Furthermore, modified poly(dicarboxylic acid multiol esters) can be mixed with suitable biocompatible organic solvents and injected or realized as implants. The carriers are suitable for controlled active ingredient release in human and veterinary medicine. | 2017-06-01 |
20170151335 | SKIN EXTERNAL PREPARATION AND SKIN IRRITATION-REDUCING METHOD - Provided is a skin external preparation including a drug and nanometer-size molecular assemblies. The molecular assemblies contain an amphiphilic block copolymer having a hydrophilic block chain including a sarcosine-derived structural unit and a hydrophobic block chain including a hydroxy acid-derived structural unit. The skin external preparation according to the present invention may reduce skin irritation caused by the drug, be very safe, and have excellent pharmacological effects, even when a drug that is generally difficult to be transdermally administered due to its strong skin irritation is contained therein. | 2017-06-01 |
20170151336 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS FABRICATION METHOD AS WELL AS APPLICATION - The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (HA), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the CD44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug. | 2017-06-01 |
20170151337 | HIGH PENETRATION COMPOSITION AND USES THEREOF - The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate. | 2017-06-01 |
20170151338 | COMPOSITIONS OF PEGYLATED SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS AND METHODS OF PREPARING - The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability. | 2017-06-01 |
20170151339 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF - Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases. | 2017-06-01 |
20170151340 | Conjugates Containing Hydrophilic Spacer Linkers - Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations. | 2017-06-01 |
20170151341 | SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES - The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same. | 2017-06-01 |
20170151342 | TARGETED INTERFERONS DEMONSTRATE POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES - Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-α) or interferon beta (IFN-β). | 2017-06-01 |
20170151343 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE - The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer. | 2017-06-01 |
20170151344 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE - The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer. | 2017-06-01 |
20170151345 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The technology described herein is directed to methods and compositions directed to the treatment of cancer, e.g. using multifunctional receptor targeted cancer therapeutics. | 2017-06-01 |
20170151346 | DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE - The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders. | 2017-06-01 |
20170151347 | FUNCTIONALIZED NANOPARTICLES WITH ENCAPSULATED CARGO AND METHOD OF THEIR SELF-ASSEMBLY - This application discloses the approach of synthesizing cellulose acetate nanoparticles and rods which may have a chemically functionalized surface and an encapsulated cargo load. Functionalization and/or loading of the cargo are made through a physical mixing of the functionalizing and/or cargo components in the synthesizing bath. This can result in particles with functionalized surfaces with various functional groups, as well as active cargo load encapsulated in the particles. The encapsulated cargo includes but is not limited to biologically, chemically, and optically active substances. | 2017-06-01 |
20170151348 | MYOSTATIN INHIBITION FOR ENHANCING MUSCLE AND/OR IMPROVING MUSCLE FUNCTION - The present invention relates to methods for inhibitiing myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). Some of the methods involve delivering genes to cells using gene delivery or other delivery techniques known in the art in order to inhibit myostatin. Examples of genes to be delivered are genes encoding proteins such as Follistatin, Follistatin-related gene-1 (FLRG-1), growth differentiation factor associated protein-1 (GASP-1) and myostatin precursor propeptide. The genes can be delivered using, for example, a recombinant Adeno-associated virus (rAAV), lentivirus or equine-associated virus capable of infecting the cells. Following introduction, the genes are expressed in the cell body of the infected cell and the encoded proteins are secreted systemically. In other methods of the invention, expression of proteins such as activin IIb and myostatin is inhibited by oligonucleotide techniques to effect muscle enhancement. All the methods have applications in the treatment of musculoskeletal and neurodegenerative disorders among others, as well as enhancing muscle in livestock. | 2017-06-01 |
20170151349 | PARTICLES COMPRISING PROTAMINE AND RNA IN COMBINATION WITH ENDOSOME DESTABILIZING AGENTS - The present invention relates to particles comprising protamine, RNA and at least one endosome destabilizing agent, to methods of their production and to pharmaceutical compositions or kits containing the particles. It further relates to particles comprising protamine and RNA for use in methods of treatment or prevention of diseases and to kits comprising such particles together with at least one endosome destabilizing agent. | 2017-06-01 |
20170151350 | PHOSPHORESCENT NANOPARTICLES AND THEIR USES IN BIOSENSING AND BIOIMAGING - Size-tunable phosphorescent particles may be formed through self-assembly of biocompatible linear polymers, such as chitosan and other linear polymers, that bear positive surface charges, through polyelectrolytic complexation to a polyanionic metal phosphor, such as polyanionic gold(I) phosphor (AuP). The phosphorescent hydrogel nanoparticles and thin films thereof are useful for imaging, sensing of biological molecules, detection of hypoxia, and light-emitting devices. The phosphorescent hydrogel particles can be formed from a variety of linear polymers by physical cross-linking using polyelectrolytic light-emitting species, without the need for the phosphorescent complex to be entrapped in an existing microsphere or nanosphere polymer particle. | 2017-06-01 |
20170151351 | Gd-ENCAPSULATED CARBON DOTS AND METHODS OF MAKING AND USING THEREOF - Gd-encapsulated carbonaceous dots (Gd@C-dots) hold great potential in clinical translation as Ti contrast agent for magnetic resonance imaging. However, current synthetic techniques yield particles with poor size control; hence, time-consuming size selection is often needed to obtain particles of desired sizes. Disclosed is a process whereby mesoporous silica nanoparticles are used as templates for size-controlled synthesis of Gd@C-dots. The disclosed methods involve calcining a mixture comprising a mesoporous silica nanoparticle, a gadolinium-containing compound, and a chelator, thereby forming the nanoparticles of gadolinium within the mesoporous silica nanoparticle; and removing the mesoporous silica nanoparticle from the nanoparticles of gadolinium. | 2017-06-01 |
20170151352 | IMMUNOLOGICAL DETECTION OF ALTERED CELLS - Disclosed are methods, compositions of matter, and protocols useful for the detection of altered cells in a patient. Immune cells capable of clonal expansion are engineered to produce a soluble signal upon activation and/or clonal expansion. The cells may possess a suicide gene, inducible upon administration pharmacological or light/radiation activatable, so as to eliminate the cells from body when desired. In another embodiment, immune cells produce a localized marker, the marker being visible with imaging technology. In other embodiments cells capable of non-clonal expansion are utilized. The disclosure provides means of utilizing the immunosurveillance properties of immune cells to diagnose and localize diseases associated with alteration of host cells. | 2017-06-01 |
20170151353 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS - The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. | 2017-06-01 |
20170151354 | AUGER ELECTRON THERAPY FOR GLIOBLASTOMA - A method is provided for treating or ameliorating a high-grade glioma in a patient, which method comprises intracerebral administering of a radioactive agent characterized by a short-range cytotoxic ionizing radiation by convection-enhanced delivery. Further, a radioactive agent characterized by a short-range cytotoxic ionizing radiation is provided for use in treating or ameliorating a high-grade glioma, where the agent is administered by intracerebral convection-enhanced delivery | 2017-06-01 |
20170151355 | TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER - Method of using androgen receptor and/or butyrylcholinesterase targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for the treatment and diagnosis of cancer. | 2017-06-01 |
20170151356 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases - Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD22 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. | 2017-06-01 |
20170151357 | METHOD FOR TREATING RENAL CELL CARCINOMA - Accordingly, the present invention provides a method of treating kidney neoplasia in a subject in need of treatment, by subjecting the patient to SIRT. | 2017-06-01 |
20170151358 | GARMENT SANITIZER - The invention relates to a garment sanitizing device ( | 2017-06-01 |
20170151359 | LIGHT DISINFECTION SYSTEM AND METHOD - A lighting system includes a light source configured to generate light toward one or more surfaces or materials to inactivate one or more pathogens on the one or more surfaces or materials. The light includes an inactivating portion having wavelengths in a range of 280 to 380 nanometers. | 2017-06-01 |
20170151360 | DEVICE FOR EVAPORATING VOLATILE SUBSTANCES - The invention relates to a device for evaporating volatile substances, comprising a heat source ( | 2017-06-01 |
20170151361 | WICK FOR VOLATILE SUBSTANCE EVAPORATORS - The present invention relates to a wick for volatile substance evaporators formed from a strip ( | 2017-06-01 |
20170151362 | TABLE TOP SCENT DISPENSING DEVICE AND METHOD - A method of operating a scent dispensing device includes starting operation of an air mover to move air. A motor orients a scent cartridge in a first orientation in which an outlet of a first chamber of the scent cartridge is fluidly communicatively coupled with a port of the scent dispensing device. A direction and an amount of movement from the first orientation to orient the scent cartridge in a second orientation in which an outlet of a second chamber of the scent cartridge is fluidly communicatively coupled with the first port of the scent dispensing device are determined. The scent cartridge is then oriented in the second orientation. A consumable scent cartridge includes a housing having walls that define chambers arrayed about a rotational axis and consumable scent media received in at least two of the chambers. | 2017-06-01 |
20170151363 | PORTABLE MULTI-FRAGRANCE COMPOSITIONAL DISPENSING SYSTEM AND METHODS OF USE - The present invention relates to a portable multi-fragrance compositional dispensing system comprising at least an aqueous based composition and a volatile solvent based composition, wherein the system comprises at least two separate containers, two separate dispensers, and two separate exit orifices therein. Methods of using the system for providing a longer lasting fragrance is also encompassed by the present invention. | 2017-06-01 |
20170151364 | MULTI-COMPONENT FRAGRANCE DISPENSING APPARATUS - The present invention relates to a multi-component fragrance dispensing apparatus comprising at least an aqueous based composition and a volatile solvent based composition, wherein the apparatus comprises at least two separate containers, two separate dispensers, and two separate exit orifices therein. Methods of using the apparatus for providing a longer lasting fragrance is also encompassed by the present invention. | 2017-06-01 |
20170151365 | HEMOSTATIC DEVICES - Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon. | 2017-06-01 |
20170151366 | JOINING AND/OR SEALING TISSUES THROUGH PHOTO-ACTIVATED CROSS-LINKING OF MATRIX PROTEINS - A method of joining and/or sealing tissues in a surgical procedure or medical treatment, comprising the steps of: (1) applying a matrix protein, a photoactivatable metal-ligand complex and an electron acceptor to a tissue portion; (2) irradiating said tissue portion to photoactivate the photoactivatable metal-ligand complex; thereby initiating a cross-linking reaction of the matrix protein to seal said tissue portion or join said tissue portion to an adjacent tissue portion. | 2017-06-01 |
20170151367 | DRY DERMAL FILLER COMPOSITIONS AND METHODS OF RECONSTITUTION - Dermal fillers are provided, particularly hyaluronic acid-based dermal fillers containing additives, for example, unstable additives, the dermal fillers being provided in an anhydrous state for extended shelf life. | 2017-06-01 |
20170151368 | AUTO-POLYMERIZABLE PROSTHETIC MATERIAL AND POLYMERIZED, FRACTURE-TOUGH PROSTHETIC MATERIAL WITH INCREASED COLOUR STABILITY - The subject matter of the invention is an autopolymerisable two-component prosthetic base material and a method for its production comprising A) at least one liquid monomer component, and B) at least one powdered component, whereby the prosthetic material comprises in components (A) and/or (B) (i) at least one initiator or one initiator system for autopolymerisation, (ii) core-shell particles modified by an elastic phase, and (iii) at least one urethane (meth)acrylate. | 2017-06-01 |
20170151369 | MULTIPLE-LAYER IMMUNE BARRIER FOR DONOR CELLS - A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described. | 2017-06-01 |
20170151370 | BONE MARROW ASPIRATE ENHANCED BONE GRAFT - A method of preparing a bone graft. An osteoconductive matrix is placed in a receptacle. Bone marrow aspirate is provided that includes plasma, progenitor cells, hematopoietic cells, endothelial cells, red blood cells, white blood cells, platelets, bone, cartilage, thrombus or combinations thereof. The bone marrow aspirate is passed through the receptacle. At least a portion of bone marrow aspirate is retained in the receptacle. The portion of the bone marrow aspirate retained in the receptacle becomes associated with the osteoconductive matrix to form the bone graft. | 2017-06-01 |
20170151371 | Methods of Forming a Porous Ceramic Shaped Article and Porous Ceramic Products - A method for making a porous, chemically bonded ceramic shaped article comprises i) providing a precursor powder mixture comprising polymer particles and a ceramic self-setting cementious powder; ii) preparing a shaped article from a paste comprising the precursor powder mixture and an aqueous liquid; and iii) immersing the shaped article in an immersing liquid in which the polymer particles are soluble, for a period of time of from about 10 minutes to about two weeks to dissolve the polymer particles in the immersing liquid, thereby creating pores in the shaped article. A porous, chemically bonded ceramic shaped article having interconnected pores, a total porosity of at least about 50%, and a macroporosity of at least about 30% can be formed by such methods. | 2017-06-01 |
20170151372 | RUBBER OR ELASTOMER MEDICAL DEVICE AND METHOD FOR PRODUCING THE SAME - Provided are a rubber or elastomer medical device that is excellent in sliding properties, low protein adsorption properties, low cell adsorption properties, and the durability of these properties (the ability to reduce deterioration of sliding properties, low protein adsorption properties, and low cell adsorption properties), and a method for producing the device. The present invention relates to a rubber or elastomer medical device having a surface treatment layer on at least a part of its rubber or elastomer surface, the surface treatment layer including a functional layer formed of a silane compound containing a polyoxyalkylene group, a metal salt-containing hydrophilic group, a halogen salt-containing hydrophilic group, or a fluorine-containing hydrophobic group. | 2017-06-01 |
20170151373 | ANTIMICROBIAL SOLUTIONS WITH ENHANCED STABILITY - Provided are antimicrobial solutions, including catheter lock solutions. In some embodiments, the solution contains an antibiotic (e.g., minocycline or trimethoprim), EDTA, and an alcohol (e.g., ethanol), wherein the pH of the solution is adjusted to about 6-8 to reduce precipitation. Methods of using the solutions and kits are also provided. | 2017-06-01 |
20170151374 | METAL MEDICAL DEVICE AND METHOD FOR PRODUCING THE SAME - Provided are a metal medical device that is excellent in sliding properties, low protein adsorption properties, low cell adsorption properties, and the durability of these properties (the ability to reduce deterioration of sliding properties, low protein adsorption properties, and low cell adsorption properties), and a method for producing the device. The present invention relates to a metal medical device having a surface treatment layer on at least a part of its metal surface, the surface treatment layer including a primer layer formed of an alkoxysilane or a modified alkoxysilane containing a substituted alkoxy group, and a functional layer on the primer layer, the functional layer being formed of a silane compound containing a polyoxyalkylene group, a metal salt-containing hydrophilic group, a halogen salt-containing hydrophilic group, or a fluorine-containing hydrophobic group. | 2017-06-01 |
20170151375 | BIOCOMPATIBLE, BIOMIMETIC AMPHOLYTE MATERIALS - New ampholyte biomaterial compounds containing ampholyte moieties are synthesized and integrated into polymeric assemblies to provide hydrophilic polymers exhibiting improved biocompatibility, haemocompatibility, hydrophilicity non-thrombogenicity, anti-bacterial ability, and mechanical strength, as well as suitability as a drug delivery platform. | 2017-06-01 |